Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial

  • J Clin Oncol. 2026 Nov;44(31):3036-3047. doi: 10.1200/JCO-26-00602.
Jian Zhang  1 ,  Quchang Ouyang  2 ,  Qingyuan Zhang  3 ,  Huihui Li  4 ,  Xu Wang  5 ,  Ying Wang  6 ,  Yongmei Yin  7 ,  Shusen Wang  8 ,  Yuanting Gu  9 ,  Tao Sun  10 ,  Jingfen Wang  11 ,  Xinhong Wu  12 ,  Fanfan Li  13 ,  Xi Chen  14 ,  Man Li  15 ,  Jin Yang  16 ,  Hua Yang  17 ,  Zhengkui Sun  18 ,  Jianyun Nie  19 ,  Xiaojia Wang  20 ,  Jian Liu  21 ,  Xianjun Tang  22 ,  Hao Wang  23 ,  Zhan Huang  24 ,  Weimin Xie  25 ,  Wenyan Chen  26 ,  Fan Li  27 ,  Yuee Teng  28 ,  Shuqun Zhang  29 ,  Ru Zeng  30 ,  Wenhui Wang  31 ,  Lixia Ma  32 ,  Yongli Gao  33 ,  Haijun Yu  34 ,  Xiguang Cao  35 ,  Yan Qing  35 ,  Xiaoping Jin  35 ,  Junyou Ge  36 ,  Hongxia Wang  1 ,  Xichun Hu  1
Affiliations
  • 1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • 2. Breast Internal Medicine Department, Hunan Cancer Hospital, Changsha, China.
  • 3. Breast Internal Medicine Ward 1, Harbin Medical University Cancer Hospital, Harbin, China.
  • 4. Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • 5. Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
  • 6. Breast Internal Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • 7. Breast Disease Center, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • 8. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • 9. Department of Breast Surgery II, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • 10. Department of Breast Medicine 1, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
  • 11. Department of Breast Ward 2, Linyi Cancer Hospital, Linyi, China.
  • 12. Breast Center, Hubei Cancer Hospital, Wuhan, China.
  • 13. Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
  • 14. Oncology Department, The 900th Hospital of Joint Logistics Support Force, Fuzhou, China.
  • 15. Breast Tumor Department, The Second Hospital of Dalian Medical University, Dalian, China.
  • 16. Oncology Department, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • 17. Oncology Department, Affiliated Hospital of Hebei University, Baoding, China.
  • 18. Oncology Department, Jiangxi Cancer Hospital, Nanchang, China.
  • 19. The Second Ward of Breast Surgery, Yunnan Cancer Hospital, Yunnan, China.
  • 20. Department of Gynecological Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • 21. Breast Oncology Department, Fujian Cancer Hospital, Fuzhou, China.
  • 22. Breast Tumor Center, Chongqing University Cancer Hospital, Chongqing, China.
  • 23. Department of Oncology, Sichuan Cancer Hospital, Chengdu, China.
  • 24. Department of Breast, Thyroid, Head and Neck Surgery, Yuebei People's Hospital, Shaoguan, China.
  • 25. Department of Breast, Bone and Soft Tissue Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
  • 26. Oncology Department, Nanchang People's Hospital, Nanchang, China.
  • 27. Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • 28. Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
  • 29. Oncology Department, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • 30. Oncology Department, The First Affiliated Hospital of Xiamen University, Xiamen, China.
  • 31. Department of Thyroid and Breast Surgery, Weifang People's Hospital, Weifang, China.
  • 32. Oncology Department, Jilin Provincial Cancer Hospital, Changchun, China.
  • 33. Department of Oncology, Linyi People's Hospital, Linyi, China.
  • 34. Breast and Urological Oncology (Chemoradiotherapy) Department, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • 35. Clinical Research Center, Sichuan Kelun-Biotech Biopharmaceutical Co, Ltd, Chengdu, China.
  • 36. National Engineering Research Center of Targeted Biologics, Chengdu, China.
Abstract

Purpose: To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/Metastatic Breast Cancer (BC).

Methods: In this phase III, open-label, multicenter trial (ClinicalTrials.gov identifier: NCT06968585), conducted at 57 centers in China, adult patients with HER2-positive, unresectable/metastatic BC who had received prior trastuzumab and a taxane were randomly assigned (1:1) to receive trastuzumab botidotin or trastuzumab emtansine. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR), using an intention-to-treat analysis. In a prespecified interim analysis of PFS per BICR, trastuzumab botidotin Met the prespecified superiority boundary (P < .0001). We report here the prespecified final analysis of PFS.

Results: Between July 18, 2023, and April 26, 2024, 365 patients were randomly assigned to trastuzumab botidotin (n = 182) or trastuzumab emtansine (n = 183). At data cutoff (median follow-up, 14.9 months), trastuzumab botidotin resulted in longer PFS than trastuzumab emtansine (median, 11.1 v 4.4 months; hazard ratio [HR], 0.39 [95% CI, 0.30 to 0.51]; nominal P < .0001). Benefit was consistent across subgroups, including those defined by prior lines of anti-HER2 therapy, prior pertuzumab or anti-HER2 tyrosine kinase inhibitors, and visceral metastases. The objective response rate was 76.9% (95% CI, 70.1 to 82.8) with trastuzumab botidotin and 53.0% (95% CI, 45.5 to 60.4) with trastuzumab emtansine. Overall survival data were immature (medians not reached in either group; HR, 0.62 [95% CI, 0.38 to 1.03]). Grade ≥3 treatment-emergent adverse events occurred in 127 (69.8%) and 116 (63.7%) patients in each group, respectively. Ocular treatment-related adverse events had a high incidence with trastuzumab botidotin; however, with a protocol-defined algorithm, most events generally recovered or resolved. Trastuzumab botidotin treatment had low incidences of pulmonary, hematologic, hepatic, and GI toxicities.

Conclusion: Among patients with HER2-positive advanced BC previously treated with trastuzumab and a taxane, trastuzumab botidotin resulted in significantly longer PFS than trastuzumab emtansine, with a distinct safety profile.

Products